Trisalus Life Sciences Inc TLSI

$3.22 -0.03 (-0.92%)

Valuation

Market cap
200,119,000
Revenue TTM
$45,150,000
Net income TTM
$-39,230,000
P/E (trailing)
0.00
P/E (forward)
—
Profit margin
-86.89%
Debt to equity
5.05

Trading

Volume
185,300
Avg volume
279,106
Day's range
$3.20 – $3.49
Shares out
61,575,000
Stochastic %K
2%
Beta
0.50
Analysts
Strong Buy
Price target
$10.40

Price

Company profile

TriSalus Life Sciences, Inc. engages in the research, development, and commercialization of drug delivery technology platform and immuno-oncology therapeutics to improve outcomes for patients with difficult-to-treat liver and pancreatic cancers in the United States. It offers Pressure-Enabled Drug Delivery (PEDD) infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization an...

Show more

TriSalus Life Sciences, Inc. engages in the research, development, and commercialization of drug delivery technology platform and immuno-oncology therapeutics to improve outcomes for patients with difficult-to-treat liver and pancreatic cancers in the United States. It offers Pressure-Enabled Drug Delivery (PEDD) infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial for treating locally advanced pancreatic cancer. The company is also developing nelitolimod, an investigational immunotherapeutic in Phase 1 clinical trial for the treatment of uveal melanoma, intrahepatic cholangiocarcinoma, hepatocellular carcinoma, and pancreatic cancer. It serves interventional radiologists, IR technicians, medical oncologists, nursing support, and value analysis committee staff. The company was founded in 2009 and is headquartered in Westminster, Colorado.

Industry
Medical Devices
Sector
Healthcare
Phone
888 321 5212
Website
https://trisaluslifesci.com
Address
6272 West 91st Avenue, Westminster, United States

Latest news

Stocktwits

EarningsInsider Nov 10, 2:17 PM
https://www.marketbeat.com/earnings/reports/2026-11-10-trisalus-life-sciences-inc-stock/ $TLSI TriSalus Life Sciences Earnings Transcript
0 replies
StocktwitsEarnings Nov 10, 1:11 PM
$TLSI Q3 '26 Earnings Results & Recap • Reported GAAP EPS of -$0.15 up 84.38% YoY • Reported revenue of $12.88M up 11.32% YoY
0 replies
Merlintrader Nov 8, 3:56 PM
$TLSI: Q3 results call Tue Nov 10, 8:30 AM ET; presents Wed Nov 11, 11:30 AM ET. Call: https://register-conf.media-server.com/register/BIcaa930c9ce7a4385bbf4270f518f8d1d Fri close $3.25, below SMA50 ($4.28), below SMA200 ($4.35), RSI 34. Interactive chart with bull/bear scenarios: https://justcharts.merlintrader.com/#TLSI Not investment advice.
1 replies
TheRagnirLothbrok Nov 5, 12:21 AM
Ticker SCAG had huge news today: Scage Future Enters into Strategic Cooperation Agreement with China Huaye Group SCAG has only 1.3 million shares float - Chinese - Watch it 👀🚀 $TLSI $GVH $RILY SP{
0 replies
AccuRoger Oct 31, 6:26 PM
$TLSI Three of the authors in this new article have a relationship with Trisalus. The results speak to the company’s strength. Quote Compared with transarterial chemoembolization, transarterial radioembolization and percutaneous ablation were associated with higher odds of CPN (adjusted odds ratios 2.19 and 1.84; both p<0.001). This association was observed in both baseline waitlist-dropout risk groups. https://www.ovid.com/jnls/hepcomm/fulltext/10.1097/hc9.0000000000001074~complete-necrosis-of-hcc-improves-recurrence-free-and
0 replies
CapitalWhale Oct 10, 1:27 AM
$TLSI news would be nice
1 replies
Johnbu1234 Oct 2, 6:23 AM
$TLSI Imagine news tomm
1 replies
AccuRoger Sep 30, 3:46 PM
$TLSI This is new funding for PRECLINICAL work using Nelitolimod (SD-101) for Ovarian Cancer. Quote Working with mouse models first, Dr. Cubillos-Ruiz’s lab will validate key findings in human HGSOC tumor specimens from Weill Cornell Medicine’s biobank. By identifying the immune cells and biological processes involved, the researchers hope to understand why ovarian cancer is resistant to existing immunotherapies and how SD-101 overcomes this resistance to build lasting protection. Since SD-101 is being tested in clinical trials for melanoma, pancreatic cancer and liver-related tumors, researchers may translate the findings to ovarian cancer more quickly if the results continue to be encouraging. https://news.weill.cornell.edu/news/2026/09/fall-grants-roundup
1 replies